Scabies Clinical Trial
Official title:
Veron Scabies Education and Eradication Program
The purpose of this project is to develop a community scabies eradication and education program for the highly endemic areas surrounding the Veron community on the eastern tip of the Dominican Republic. It proposes the use of oral Ivermectin as a replacement for topical Lindane--a readily available medical formulation, pesticide, and environmental toxin that is reported to be banned in the Dominican Republic as well as over 80 other countries throughout the world.
Introduction
The Secretaría de Estado de Salud Pública y Asistencia Social public health clinic in Veron,
Dominican Republic continually reports a subjectively high prevalence and incidence of
scabies infections among its general patient population without any means of direct
measurement, proper intervention, or control, raising concerns that long-term infestation may
lead to multiple other secondary medical and environmental problems.
The purpose of this project is to develop a community scabies eradication and education
program for the highly endemic areas surrounding the Veron community. It proposes the use of
oral Ivermectin as a replacement for topical Lindane, a readily available and prescribed
pesticide and environmental toxin that is reportedly banned for all uses in the Dominican
Republic as well as over 80 other countries throughout the world (Boffa, Brough, & Ead, 1995;
Davies, Dedhia, Mergade, Banquet, & Maibach, 1983).
Ivermectin, on the other hand, is a remarkably safe, effective, cost-comparative oral
medication with a substantially broader scope of coverage, duration of effectiveness, and
ease of delivery and compliance when compared to Lindane, as well as over 20 years of use in
global mass eradication campaigns for other parasites on the order of more than 50 million
doses to date (Alexander, Bockarie, Kastens, Kazra, & Alpers, 1998; del Guidice, Chosidow, &
Caumes, 2003; Madan, Jaskiran, Gupta, & Gupta, 2001).
Specific program goals include: the quantification of community disease prevalence, a
statistically significant reduction in both scabies incidence as well as secondary disease
sequelae, improved community scabies awareness and prevention abilities, and decreased
environmental impact on the Veron area by eliminating the use of Lindane for scabies
treatment.
The research is designed to employ a door-to-door survey and treatment campaign in a typical
Veron neighborhood aimed at evaluating and treating every member in this target population to
create a mass prophylaxis that breaks the parasite-host cycle. Another round of treatment
will occur 6 months later, per pharmacologic dosage interval recommendations (del Guidice et
al., 2003).
Individual and group scabies education programs will occur at the Veron clinic, as well as at
the local schools to target the highly susceptible youth populations throughout the Veron
area.
Incidence measurements will occur on a monthly basis for one year after program start,
coinciding with two 6-month treatment intervals. At the end of one year, final scabies
prevalence and incidence data will be evaluated for statistical significance. While mass
treatments will cease at this time, oral Ivermectin will become the standard of care for
ectoparasite coverage at the Veron clinic assuming a statistically significant reduction in
scabies prevalence is achieved.
To date, no mass scabies eradication programs using oral Ivermectin have been reported in the
Caribbean, despite it remarkable success in other countries against scabies as well as other
parasites, namely onchocerciasis and filariasis (Walker & Johnstone, 2000; Walton & Holt,
2004). This project has the potential to be an important contribution to the effort to
eradicate a source of significant morbidity for both the people of Veron and the global
community as a whole.
Methodology
The Veron Scabies Eradication and Education Program will obtain all its priority population
data via door-to-door interviews within the Barrio Nuevo neighborhood.
A survey team of medical personnel will walk door-to-door program in an attempt to survey and
treat every inhabitant of Barrio Nuevo, unless there is refusal or absolute
contraindications. Subjects will first be informed of the program and its intent, asked to
sign a letter of patient confidentiality, and assigned a number identifier for tracking
purposes.
After consent is obtained, a survey will be administered to collect basic demographic
information, scabies knowledge indicators, as well as pertinent past and current medical
history related to scabies infection and contraindications to treatment with Ivermectin.
The subject will then be asked to undergo a brief skin exam that assesses scabies infectivity
and results recorded using the following criteria: the presence of erythematous popular,
vesicular, pustular, or bullous lesions associated with itching. Information will be recorded
and used to guide treatment protocol.
After the skin exam, subjects will be instructed on scabies medical treatment and prevention,
given a patient information and education pamphlet, asked if they have any specific questions
or concerns, informed of ongoing community scabies education workshops at the clinic, and
instructed to return to the clinic in 2 weeks if they have an active scabies infection.
Otherwise, they will be informed that the researchers will return to their neighborhood each
month to collect more information and in 6 months to administer another treatment.
Finally, the subject will be given 200μg/kg oral Ivermectin dosed by height if they are male
or non-pregnant/non-lactating female, 5 years of age or older, and taller than 90 cm.
If the subject is a female and of childbearing age (still menstruating on a monthly basis),
not currently menstruating, not able to show proof of using oral contraceptives (birth
control pills) or injectable contraceptives (scheduled Depo Provera), not surgically sterile
(hysterectomy or tubal ligation) they will be asked to undergo a rapid urine pregnancy test.
If the test is negative they will be given 200μg/kg oral Ivermectin dosed by height.
If the subject is knowingly pregnant or lactating, the rapid pregnancy test is positive, or a
child under 5 years and shorter than 90 cm they will be instructed on how to properly use
Permethrin 5% lotion and given a 60gm bottle.
This protocol will be followed until every household is visited and treated within Barrio
Nuevo at time = 0 and again at time = 6 months.
Investigators will conduct monthly scabies incidence surveys via door-to-door skin checks
within Barrio Nuevo looking for current scabies symptomatology and recording results on the
form described above.
At the end of one year, final scabies prevalence and incidence data will be evaluated for
statistical significance. While mass treatments will cease at this time, oral Ivermectin will
become the standard of care for ectoparasite coverage at the Veron clinic assuming a
statistically significant reduction in scabies prevalence is achieved.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02572986 -
A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies
|
Phase 3 | |
Completed |
NCT00884728 -
Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory
|
N/A | |
Completed |
NCT05025696 -
Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies
|
N/A | |
Completed |
NCT04205669 -
Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon
|
Phase 4 | |
Completed |
NCT02254564 -
PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
|
||
Not yet recruiting |
NCT06404333 -
Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)
|
Phase 2 | |
Completed |
NCT03676140 -
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 3 | |
Recruiting |
NCT05875441 -
Efficacy and Safety Study of Moxidectin in Adults With Scabies
|
Phase 2 | |
Completed |
NCT02978508 -
Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
|
Phase 3 | |
Recruiting |
NCT04332068 -
Ivermectin Safety in Small Children
|
Phase 2 | |
Recruiting |
NCT04844905 -
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
|
Phase 3 | |
Not yet recruiting |
NCT06380452 -
Therapy for Scabies With Two Differently Concentrated Permethrin Creams
|
Phase 3 | |
Completed |
NCT02485717 -
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
|
Phase 3 | |
Completed |
NCT02485704 -
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
|
Phase 3 | |
Recruiting |
NCT05310734 -
PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
|
Phase 4 | |
Recruiting |
NCT04931680 -
Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
|
||
Completed |
NCT06396507 -
Sulfur vs. Different Regimes of Permethrin for Scabies
|
Phase 3 | |
Completed |
NCT05862701 -
Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies
|
Phase 1 | |
Not yet recruiting |
NCT05500326 -
Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)
|
Phase 2 | |
Recruiting |
NCT04814511 -
Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)
|
Phase 3 |